Phase i study of the antiangiogenic antibody bevacizumab and the mtor/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity
Answers
Answered by
0
please see on the branlist
Similar questions